Tirzepatide (Tirz) Research Peptide

Tirzepatide is a synthetic dual-receptor agonist with activity at both GIP and GLP-1 receptors.

• A C20 fatty-diacid component supports albumin binding and prolongs exposure.
• Tirz and Tirz peptide are informal abbreviations, not separate compounds.

Tirzepatide activates the receptors targeted by the native incretin hormones GIP and GLP-1.

• Both pathways participate in glucose-dependent insulin secretion, while GLP-1 activity also contributes to glucagon regulation and gastric emptying.
• Its dual-receptor design distinguishes it from semaglutide; it does not include the glucagon-receptor activity of retatrutide.
• This category covers structure, receptor signaling, formulation, storage, testing, and comparative research.

The evidence base includes preclinical studies, controlled trials, and data for authorized prescription products.

• Approval applies to named products and indications, not every material advertised as tirzepatide.
• Research-grade, compounded, and regulated formulations may differ in manufacturing controls, excipients, concentration, and clinical evidence.